Ralaniten

Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]

Ralaniten
Clinical data
Other namesEPI-002
Drug classNonsteroidal antiandrogen
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H27ClO5
Molar mass394.892 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". J. Clin. Invest. 123 (7): 2948–60. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
  2. McEwan, Iainj; Monaghan, Amye (2016). "A sting in the tail: The N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
  3. Maughan BL, Antonarakis ES (2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Curr Treat Options Oncol. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.